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Background: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed
to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of
patients with early type 2 diabetes.
Methods: 125 diabetic subjects drawn from Dr. Shariati outpatient’s clinic list and 153 non- diabetic subjects who
were the relatives in law of diabetic participants were recruited. Participants with type 2 diabetes were free of clinical
evidence of cardiovascular disease and renal involvement. Two groups of diabetic and control were further divided
into two subgroups of hypertensive (known case of HTN or blood pressure ≥140/90 mmHg) and normotensive,
and anthropometric characteristics, metabolic biomarkers as well as markers of subclinical atherosclerosis including
Carotid intima media thickness (CIMT), flow mediated dilation (FMD) and Ankle Brachial Index (ABI) were measured.
Results: Diabetic group with a mean age of 49.9 ± 7.5 years had significantly higher CIMT (0.64 ± 0.14 vs 0.76 ± 0.19,
p = 0.001) and lower FMD (16.5 ± 8.1 vs 13.3 ± 7.1, p = 0.003) and ABI (1.2 ± 0.1 vs 1.1 ± 0.1, p = 0.01) than control with
mean age of 52.9 ± 10.1 years. 34% of control and 59.2% of diabetic were hypertensive. Fasting blood sugar, insulin
levels and calculated insulin resistance index of HOMA IR. of hypertensive subjects were higher than normotensive
subjects in both groups of diabetic and non-diabetic. Similar pattern was presented for measured inflammatory mediators
of hs-CRP and IL-6. Among subclinical atherosclerosis markers, only CIMT was significantly different between hypertensive
and normotensive subjects in both groups. In adjusted linear regression analysis, a constant significant association existed
between age and CIMT, ABI and FMD in non-diabetic, while in diabetic, age only correlated with CIMT and not the
other two markers. In multiple regression model, HTN was recognized as a risk factor for increasing CIMT (OR = 2.93,
95% CI = 1.03-8.33, p = 0.04) but not attenuating FMD or ABI.
Conclusions: Since FMD and CIMT may measure a different stage of subclinical atherosclerosis in diabetic patients,
influence of HTN on these markers might be different.
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Type 2 diabetes mellitus (T2DM) is a chronic disease that
comprises an array of dysfunctions resulting from the
combination of resistance to insulin action and inadequate
insulin secretion. Patients with diabetes are in need of
continuous medical care and self-management education
to prevent acute complications and reduce the risk of long-
term complications. Worldwide, the number of patients* Correspondence: fakhrzad@tums.ac.ir
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unless otherwise stated.with diabetes is increasing mostly because of aging,
urbanization, and increased prevalence of obesity and
physical inactivity. Beside the severe microvascular com-
plications, patients with T2DM, are at increased risk of
macrovascular complications including coronary artery
disease (CAD) [1,2]. The process of accelerated and pre-
mature atherosclerosis in diabetic leads to an increased
risk of cardiovascular events. It has been shown that
diabetic subjects are twice as likely to have a heart attack
or stroke. Indeed, myocardial ischemia, caused by athero-
sclerotic involvement of coronary arteries, more frequently
occurs without prior symptoms in these patients. In factLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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before ischemic symptoms occur and before treatment is
started. Early recognition of asymptomatic atherosclerosis
in diabetes would be certainly important in reducing the
risk of diabetic macrovascular complication and improve-
ment of the prognosis. Clinical manifestations of athero-
sclerosis occur mainly in coronary arteries, lower extremity
arteries, and carotid arteries.
Atherosclerosis can be assessed using non-invasive tech-
niques, such as carotid intima-media thickness measure-
ment (CIMT) [3], brachial artery flow-mediated dilatation
test (FMD) [4] and ankle-brachial index (ABI) [5,6].
CIMT as measured by B-mode ultrasound represents
the combined thickness of the intimal and medial layers
of the carotid artery and represents an important predictive
factor which favorably correlates with the risk of myocardial
infarction and stroke, even after excluding the impact of
other cardiovascular disease risk factors [7].
Endothelial dysfunction, characterized by a reduced bio-
availability of endothelium-derived nitric oxide, is probably
one of the earliest components of atherosclerosis [8]. Pres-
ence of endothelial damage as defined by abnormal FMD
levels predicts adverse cardiovascular outcomes [9].
The ABI, which is the ratio of systolic pressure at the
ankle to that in the arm, is a simple, inexpensive and
useful method for assessing peripheral artery disease.
Meta-analyses of large observational studies with long-term
follow-up have reported that ABI is associated with coron-
ary heart events independent of traditional Framingham
variables [10].
Several factors have been proved to affect the risk of
atherosclerosis, among them hypertension is a well-
established- traditional risk factor. Clinical trials have
shown that, in the highest quintile of diastolic pressure,
even with the added risks of high cholesterol and smoking,
hypertension still contributes significantly to risk for ath-
erosclerosis [11]. Considering the fact that atherosclerosis
is also an accelerated process in diabetic subjects we
aimed to assess the hypertension – associated additive
vascular effects on surrogate markers of atherosclerosis
in diabetic subjects in the absence of other cardiovascular
risk factors. In this regard the impact of presence or ab-
sence of hypertension on endothelial function (measured
by FMD), and structure (measured by CIMT), and also on
peripheral arterial disease (measured by ABI) was assessed
in subjects with and without diabetes.
Methods and materials
Subjects
This case- control study was performed in the Endocrin-
ology and Metabolism Research Institute (EMRI) of Tehran
University of Medical Sciences. A total of 125 diabetics and
153 non- diabetic subjects as control group were recruited
in this study. The participants were drawn from the list ofdiabetic patients who attended diabetes outpatient clinic at
Dr. Shariati Hospital; Tehran, Iran; for regular follow-up
between January to August 2010. The control group was
composed of healthy subjects.
The inclusion criteria were defined as both sexes, aged
between 20-65 years. Current or previous smokers, subjects
with symptomatic or previous history of cardiovascular
disease, myocardial infarction, diabetic foot, renal failure
(GFR < 90 cc/min), known case of malignancy, cirrhosis
and other severe disorders were excluded from the study.
All the participants had undergone the Exercise stress test
based on Bruce exercise protocol with negative result.
For all diabetic participants retinoscopy was performed
by two ophthalmologists. The patients with proliferative
retinopathy were excluded from the study. Peripheral
neuropathy was diagnosed using the 10-gram Semmes–
Weinstein monofilament test on the plantar surface of the
feet in diabetic patients. Patients who could not reliably
sense the filament were considered as diabetic neuropathy
and excluded from the study.
In all the participants, fasting plasma sugar (FBS) and
2-h post load glucose were measured. Diabetes mellitus
was defined as patients who were using either oral hypo-
glycemic agents or patients who had a FBS ≥ 126 mg/dl, or
a 2-h post load glucose ≥ 200 mg/dl [12]. Hypertensive
patients were those who were using anti-hypertensive
agents or having a systolic blood pressure of ≥ 140 or dia-
stolic blood pressure ≥90 mmHg according to The Seventh
Report of the Joint National Committee on Prevention, De-
tection, Evaluation, and Treatment of High Blood Pressure
guideline [13].
All of the participants underwent physical examination
and anthropometric evaluations at the time of recruitment.
Height was measured with a Stadiometer Height measure-
ment device. Weight was measured on a calibrated beam
balance. Blood pressure was measured twice (5 minutes
interval) using a standard calibrated mercury sphygmoman-
ometer on both right and left hands after the participants
had been sitting for at least 10 minutes. The highest blood
pressure of two sides was considered as the participant’s
blood pressure. The protocol of study was approved by the
ethics committee of Tehran University of Medical Sciences
and the participants signed their informed consent at the
time of recruitment.
Laboratory measurement
Venous blood samples were collected in the morning after
8-12 h of fasting. The blood samples were centrifuged and
then serum was collected.
Plasma levels of glucose, triglyceride (TG), total chol-
esterol, high density lipoprotein (HDL) cholesterol, low
density lipoprotein (LDL) cholesterol, LDL cholesterol,
creatinine, blood urea nitrogen (BUN) and high sensitive C-
reactive Protein (hs-CRP) were measured by a colorimetric
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(Autoanalyzer Hitachi 902). Serum Insulin concentration
was assessed by immunoassay (ELISA) using a Bioscience
kit (Monobind kit USA). Plasma Homocysteine and HbA1c
were detected by High-performance Liquid Chromatog-
raphy (HPLC) (KNAUER, Germany), coupled with fluores-
cence detector. The Serum IL-6 was measured by ELISA
(R&D system, USA). The intra and inter-assay coefficients
of variation (CVs) for all these measurements were less
than 4% which was less than allowed CVs. A morning clean
catch midstream urine sample was collected for evaluation
of microalbuminurria.
Homeostasis model assessment (HOMA) index was cal-
culated as the product of the fasting plasma insulin level
(μ IU/mL) and the fasting plasma glucose level (mmol/L),
divided by 22.5.Cardiovascular and neurologic evaluations
CIMT
Ultrasonographic analysis of the carotid artery was
performed with a high-resolution ultrasound scanner,
equipped with a linear array 13 MHz transducer (MyLab
70 XVision, biosound esaote USA) as we reported in our
previous study [14]. Briefly, a rapid cross sectional scan-
ning followed by a longitudinal scanning of the common
carotid artery (CCA) was made in the first step to pinpoint
the possible plaques. Then the dynamic sequence images
were stored for measurement of CIMT. The CIMT was
defined as the distance between the leading edge of the
lumen-intima interface and the leading edge of the media-
adventitia interface. For precise measurement of CIMT
software (Vascular Tools 5, Medical Imaging Applications
LLC, USA) was employed. The regions of interest were
defined as 1.0 cm distal to the bifurcation, the bifurcation
and 1.0 cm proximal to the internal carotid artery in both
near and far walls. The CIMT was reported for each sub-
ject as the average of 12 measurements (6 measurements
from the right and 6 from the left carotid artery).FMD
FMD of the brachial artery was measured according to the
American College of Cardiology guidelines [15] and as we
reported previously [14]. The diameter of the right brachial
artery was measured 3–5 cm above the antecubital fossa.
Then a blood pressure cuff was inflated around the right
forearm to at least 50 mmHg above the systemic blood
pressure for 4-5 minutes. 60 seconds after cuff release, the
diameter of the brachial artery was measured. The brachial
FMD was calculated as the percentage of change in the
maximum post-occlusion diameter of the brachial artery
relative to the mean baseline diameter. All the measure-
ments were performed in the end-diastolic phase coincid-
ing with the R-wave on an electrocardiograph monitor.Every measurement was taken as the average of 3 con-
secutive cardiac cycles.
ABI measurements
For calculating the ABI, the systolic blood pressure from
both brachial, dorsalis pedis and posterior tibial artery, was
assessed while the subject stayed in the supine position for
10 minutes using a handheld Doppler. The highest blood
pressure recorded in left or right sides of dorsalis pedis or
posterior tibialis arteries was considered as numerator of
ABI and the highest blood pressure of right or left side
brachial artery was considered as denominator of ABI.
Data analysis
For data analysis the SPSS (version 18.0) was used. Nor-
mality of data distribution was evaluated by Kolmogrov-
Smirnov test. For data without normal distribution,
Mann-Whitney U test was applied. For comparing data
with normal distribution independent-samples T test was
used. Adjustment for confoundin factors was performed
using univariate analysis of variance (ANOVA). Corre-
lation of variables was demonstrated using Pearson’s and
Spearman’s correlation coefficients in normally distrib-
uted parametric and nonparametric variables respectively.
For assessment of association of variables, linear regression
and logistic regression were used for parametric and
binary variables respectively.
Results
278 subjects (125 diabetic and 153 control subjects) were
enrolled in this study. Two groups had significant difference
in respect to age, lipid and glucose profile (Table 1). Dia-
betic subjects presented with significantly higher levels of
hs-CRP compared to control group. 34% (n = 52) of control
group and 59.2% (n = 74) of diabetic subjects were hyper-
tensive (p = 0.001). The means of three measured subclin-
ical atherosclerosis indexes of CIMT, FMD and ABI were
remarkably different between two groups of diabetic and
control. These difference stayed significant even after age
and sex adjustment in multivariate analysis (P = 0.013 for
ABI, P = 0.0001 for CIMTand P = 0.01 for FMD).
We subdivided the two groups of diabetic and control
groups into two subgroups of hypertensive and non-hyper-
tensive (Table 2). In control group, the hypertensive
subjects were significantly older and had greater BMI.
Interestingly, FBS, insulin level and HOMA.IR were
higher in this subgroup. Similarly the diabetic hyperten-
sive subjects were older and had greater levels of both
LDL-cholesterol and cholesterol.
The serum levels of inflammatory mediators of IL-6 and,
hs-CRP were evaluated in these four groups and we found
that there was an increasing trend in serum concentrations
of these mediators, in a way that control-non-hypertensive
patients had the lowest and diabetic- hypertensive subjects
Table 1 Anthropometric and clinical characteristics of






Age (year) 49.9 ± 7.5 52.9 ± 10.1 0.001
Female (%) 58.3 53.6 0.4
Hypertensive subjects (%) 34 59.2 0.01
Hypertension duration (year) 0.9 ± 0.3 2.0 ± 0.7 0.001
Waist circumference (cm) 92.2 ± 10.8 94.7 ± 10.7 0.06
BMI (kg/m2) 28.5 ± 4.4 27.9 ± 4.3 0.2
Systolic BP (mmHg) 125.7 ± 16.7 134 ± 17.6 0.001
Diastolic BP (mmHG) 77.9 ± 10.7 78.2 ± 10.2 0.8
Duration of DM (year) 0 8.7 ± 6.6 0.001
Cholesterol (mg/dl) 199.9 ± 34.2 176.7 ± 41.0 0.001
Triglyceride (mg/dl) 161.4 ± 78.6 192.8 ± 107.4 0.006
HDL cholesterol (mg/dl) 46.5 ± 10.6 42 ± 10 0.001
LDL cholesterol (mg/dl) 113.6 ± 23 95.7 ± 25.4 0.001
FBS (mg/dl) 94.7 ± 12 164.1 ± 61.2 0.001
Insulin (IU/L) 8.6 ± 3.4 8.5 ± 4.5 0.9
HbA1C 5.3 ± 0.6 7.9 ± 1.7 0.001
HOMA IR 2.1 ± 1.4 3.5 ± 2.8 0.001
Creatinine 0.9 ± 0.1 0.9 ± 0.2 0.8
Hs-CRP 2.3 ± 2.6 3.3 ± 2.9 0.03
IL-6 4.5 ± 5 5.4 ± 4.8 0.1
CIMT 0.64 ± 0.14 0.76 ± 0.19 0.001
FMD% 16.5 ± 8.1 13.3 ± 7.1 0.003
FMD <5.5 n, % 4, 3.5% 14, 13.9% 0.01
FMD ≥5.5 n, % 110, 96.5% 87, 86.1% 0.01
ABI 1.2 ± 0.1 1.1 ± 0.1 0.01
The data are presented as mean ± SD; comparison of variables means in two
groups performed by Student T test; BMI = body mass index; BP = blood pressure;
HDL = high-density lipoprotein; LDL = low-density lipoprotein; FBS = fasting blood
sugar; HOMA IR = Homeostatic model assessment; hs-CRP = high sensitive
C-reactive protein; IL-6 = Interleukin 6; CIMT = Carotid Intima Media thickness;
FMD = Flow Mediated Dilatation; ABI = Ankle - Brachial Index.
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the two other groups were placed between. However this
difference did not reach a significant level.
When we looked at the insulin resistance state of these
four subgroups, we observed a similar pattern on which
control-non-hypertensive subjects having the lowest
(HOMA IR = 1.93 ± 1.39) and diabetic hypertensive having
the highest (HOMA IR = 3.89 ± 2.99) HOMA IR (Figure 1).
Looking at the subclinical atherosclerosis measures re-
vealed that in both control and diabetic groups, only CIMT
measure was significantly different between subgroups
of non-hypertensive and hypertensive subjects. The trend
of decrease in FMD and ABI values was from control-
non- hypertensive to control-hypertensive to diabetic non-
hypertensive and finally to diabetic hypertensive subjects.Evaluation of the association between atherosclerosis
markers CIMT, FMD and ABI with various parameters,
using linear regression analysis revealed different results
in diabetic and non-diabetic subjects. In non-diabetic, a
constant significant association existed between age and
CIMT, ABI and FMD, while in diabetic, age only corre-
lated with CIMT and not with the other two markers.
Table 3 presents the relation between these surrogate
markers with various parameters.
For assessment of effect of hypertension on subclinical
atherosclerosis we categorized CIMT, FMD and ABI values
into 4 groups based on 75% better values and 25% worse
values of diabetic and control groups and odds ratios (OR)
of worse value were calculated in multiple logistic regres-
sion models. In this model hypertension was recognized as
a risk factor for increasing CIMT (OR= 2.93 (1.03-8.33),
however similar scenario was not observed for diminution
of FMD and ABI (Table 4).
Adjusted for Age, sex, hypertension duration, diabetes
mellitus duration, cholesterol, triglyceride and HDL-C.
Discussion
CIMT, FMD and Peripheral artery disease (PAD), evaluated
by ABI, have been related by several studies to cardiovascu-
lar risk factors and events and their non-invasive measure-
ment makes it possible to more easily detect the initial
phases of atherosclerosis [16].
In this study first we showed that compared with non-
diabetic subjects, atherosclerosis was significantly advanced
in non-complicated diabetic subjects as this process was
assessed by three surrogate markers of CIMT, FMD, and
ABI. To our knowledge few studies has done so by simul-
taneous characterization of structural, functional and
peripheral vascular alterations in T2DM subjects without
apparent macrovascular disease. Our results are in line
with previous studies in which increased CIMT [17], an
impaired FMD and ABI [18,19] were indicated in diabetic
subjects compared to control individuals. Interestingly, in
a systematic review involving.
4019 diabetic subjects, an estimated mean difference
of 0.13 mm in IMT was observed between diabetic and
control group, a value that is similar to what we have seen
in our subjects [16]. In diabetes the accelerated vascular
disease is not restricted to the coronary circulation but also
occurs in peripheral vascular systems. In general population
an ABI less than 0.9 is regarded as an indicator of PAD and
has a high sensitivity and specificity to identify an obstruc-
tion greater than 50% in the vasculature of the lower limbs
[20]. The cut-off values for the highest sensitivity and speci-
ficity for PAD in diabetic patients, however, might be differ-
ent. In our study the mean of ABI in both groups was over
0.9 though diabetic subjects still had significantly lower
ABI than control. This could be translated into that the
need for intensive treatment of risk factors and initiation










Age (year) 50.6 ± 12.56 54.5 ± 7.8 0.04 48.7 ± 7.39 52.2 ± 7.1 0.00
Female (%) 47.1 58.1 0.27 62.4 51.9 0.22
Waist circumference (cm) 92.86 ± 7.31 96.03 ± 12.37 0.07 90.71 ± 10.89 95.21 ± 10.15 0.01
BMI (kg/m2) 26.48 ± 3.74 28.93 ± 4.33 0.00 28.49 ± 4.75 28.64 ± 3.85 0.85
Systolic BP 122.04 ± 9.90 142.26 ± 17.07 0.00 117.91 ± 11.08 140.63 ± 1563 0.00
Diastolic BP 72.25 ± 7.92 82.36 ± 9.72 0.00 73.56 ± 7.62 86.25 ± 10.77 0.00
Duration diabetes (year) 0 0 10.07 ± 7.10 6.73 ± 5.40 0.00
Cholesterol (mg/dl) 171.00 ± 37.37 180.59 ± 43.16 0.20 194.99 ± 32.16 209.43 ± 36.31 0.01
Triglyceride (mg/dl) 158.4 ± 87.05 167.31 ± 59.20 0.01 168.2 ± 88.49 209.26 ± 11.12 0.07
HDL cholesterol (mg/dl) 41.33 ± 10.25 42.41 ± 9.78 0.55 45.94 ± 10.06 47.53 ± 11.52 0.38
LDL cholesterol (mg/dl) 92.65 ± 22.72 97.74 ± 27.06 0.27 110.33 ± 21.73 119.90 ± 24.17 0.01
FBS (mg/dl) 93.10 ± 11.41 97.80 ± 12.64 0.02 155.10 ± 49.89 170.19 ± 67.45 0.17
Insulin (IU/L) 6.20 7.25 0.05 6.75 8.30 0.04
HOMA IR 1.93 ± 1.39 2.34 ± 1.25 0.04 2.84 ± 1.25 3.89 ± 2.9 0.09
Hs-CRP 2.11 ± 2.05 2.59 ± 3.37 0.28 2.88 ± 4.6 3.64 ± 5.1 0.4
IL-6 3.28 ± 1.82 3.93 ± 2.98 0.12 4.44 ± 3.21 5.47 ± 2.93 0.12
CIMT 0.61 ± 0.1 0.70 ± 0.1 0.00 0.71 ± 0.1 0.78 ± 0.2 0.00
FMD 17.08 ± 7.9 15.35 ± 8.2 0.28 14.28 ± 7.56 12.72 ± 6.84 0.28
ABI 1.17 ± 0.1 1.15 ± 0.1 0.36 1.14 ± 0.10 1.12 ± 0.11 0.32
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PAD should be considered.
In this study we showed that our hypertensive subjects
regardless of being diabetic or non- diabetic had higher
CIMT. Similarly, Mahfouz et al. [21] and Sorof et al. [22]
showed the greater value of CIMT in hypertensive subjects.
Moreover, Post-hoc analyses of the association between an-
tihypertensive treatment and CIMT in the Troglitazone
Atherosclerosis Regression Trial (TART), which assessed
CIMT progression in adults with insulin-treated type 2
diabetes, found that higher systolic blood pressure wasFigure 1 Insulin resistance status and levels of inflammatory mediato
C-HTN = control hypertensive; DM-C = diabetic normotensive; DM-HTN = diassociated with a higher CIMT progression rate [23].
Elevation of blood pressure has been shown to be associ-
ated with several alterations in the vascular system, includ-
ing enhancement of vascular tone, increased shear stress,
and activation of the sympathetic nervous and renin-
angiotensin aldosterone systems. Because these functional
and structural changes promote endothelial damage and
lead to atherosclerosis, hypertension is one of the main
causes of endothelial dysfunction [24]. In this study we did
demonstrate favorable trends for FMD and ABI impair-
ment in hypertensive versus non-hypertensive subjects,rs in diabetic and control groups. C-C = control normotensive;
abetic hypertensive.
Table 3 Linear regression analysis for evaluation of association of CIMT, FMD and ABI with different parameters in
diabetic and non-diabetic subjects
Variable CIMT FMD ABI
Non diabetic β, (P)§ Diabetic β, (P)§ Non diabetic β, (P)§ Diabetic β, (P)§ Non diabetic β, (P)§ Diabetic β, (P)§
Age 0.33 (0.01) 0.31 (0.01) -0.23 (0.02) -0.15 (0.12) 0.19 (0.04) -0.09 (0.36)
Sex -0.12 (0.2) -0.23 (0.01) 0.09 (0.38) 0.19 (0.06) 0.03 (0.73) -0.16 (0.1)
Systolic BP 0.27 (0.01) 0.14 (0.12) 0.32 (0.01) -0.04 (0.72) -0.01 (0.31) 0.03 (0.8)
Diastolic BP 0.22 (<0.01) 0.19 (0.03) -0.13 (0.19) -0.05 (0.61) -0.16 (0.08) 0.06 (0.54)
BMI -0.07 (0.45) -0.21 (0.04) -0.13 (0.2) -0.05 (0.65) 0.20 (0.04) 0.01 (0.94)
Waist circumference -0.001 (0.98) -0.24 (0.01) 0.05 (0.64) 0.04 (0.70) 0.11 (0.28) 0.00 (0.99)
HOMA IR -0.02 (0.78) -0.12 (0.2) -0.17 (0.09) 0.00 (1.00) 0.02 (0.81) -0.03 (0.75)
Hs-CRP -0.01 (0.95) 0.00 (0.97) -0.16 (0.1) 0.10 (0.37) -0.15 (0.09) -0.09 (0.33)
IL-6 0.18 (0.03) -0.07 (0.43) -0.20 (0.81) 0.13 (0.21) -0.15 (0.11) 0.08 (0.43)
BMI = body mass index; BP = blood pressure; HOMA IR = Homeostatic model assessment; hs- CRP = high sensitive C-reactive protein; IL-6 = interleukin 6; CIMT = Carotid
Intima Media thickness; FMD= flow Mediated Dilatation; ABI = Ankle - brachial index. §: adjusted for age, sex, triglyceride, total cholesterol, HDL-C and LDL-C.
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Even though we cannot clearly explain this observation, but
one explanation for lack of seeing a remarkable difference
would be that since the effect of hypertension on arteries is
not similar on all vessels due to geometrical and oscillating
shear stress properties of sites, it is predictable that hyper-
tension produce more effect on carotid rather than limb
vessels which are represented by impaired FMD and ABI
[25]. Lack of difference in ABI might be also related to the
fact that ABI is a late-onset finding in hypertensive subjects
and as was demonstrated in ABI values, none of our sub-
jects had ABI less than 0.9, a value that is the indicator of
PAD.
A close relation between hypertension and inflammation
is reported by investigators [26,27]. Pathophysiologically,
inflammation has been implicated in both endothelial
dysfunction and arterial stiffness in hypertension and it is
assumed that every mechanism leading to inflammation
will accelerate this process [27].
Here we detected an increasing trend in two basic inflam-
matory mediators of IL-6 and CRP in hypertensive subjects
no matter they were in control or diabetic group. Even
though our study was not powered enough to detect the
significant change, our data is compatible with others
and emphasizes on the link between hypertension and
inflammation, but is insufficient to reveal whether theTable 4 Hypertension as risk factor of subclinical
atherosclerosis
Diabetic Control
Adjusted OR (CI) P Adjusted OR (CI) P
CIMT (75%) 3.15 (1.03-9.56) 0.04 2.93 (1.03-8.33) 0.04
FMD (75%) 0.80 (0.22-2.88) 0.73 2.44 (0.72-8.25) 0.15
ABI (75%) 1.07 (0.39-2.91) 0.39 1.58 (0.54-4.57) 0.89
OR: Odds Ratio, CI: Confidence Interval, CIMT: Carotid Intima-Media Thickness,
FMD: Flow Mediated Dilation, ABI: Ankle Brachial Index.primary inflammation is the underlying cause of hyperten-
sion or inflammation is a product of being hypertensive.
One main finding of this study was that we demon-
strated that hypertension is an independent risk factor of
atherosclerosis in diabetes, which produces a significant
additive effect with diabetes mellitus on elevation of IMT
but not FMD or ABI. this does not mean that hypertension
did not affect the endothelial function or arterial resistance
in diabetic subjects, but we could assume that the presence
of diabetes per se is of so crucial importance for the devel-
opment of atherosclerosis (due to development and per-
sistence of a cluster of multiple interrelated metabolic
disturbances), that it over shadows the contribution of
other risk factors.
A number of risk factors have been associated with the
development of atherosclerosis in the carotid arteries.
Generally advanced age, hypertension, cigarette smoking,
hyperlipidemia and diabetes are the known factors [28]. In
our study, the only persistent factor that affects all the sur-
rogate markers of atherosclerosis in normal subjects but
not the diabetic was age. On the other hand, in diabetic
subjects, in addition to age and blood pressure, BMI also
had an effect on CIMT. Such a difference between factors
related to atherosclerosis in diabetic and control subjects
were also observed for FMD and ABI. Studies of the
correlation between risk factors of atherosclerosis and
surrogate markers of this process in different populations
have produced different results, with some showing an as-
sociation between risk factors and atherosclerosis markers
but others finding no relationship at all. Similar to our
study, Butt and Zakaria found an association between BMI
and CIMT in diabetic [17], while Taniguchi et al. [29] found
no correlation with BMI. Association of BMI with in-
creased CIMT may suggest that central fat accumulation
could accelerate the development of earlier clinically silent
stages of atherosclerosis.
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an additive effect on increased CIMT but not on FMD and
ABI on diabetic subjects. Indeed, we showed that markers
of atherosclerosis were associated with different risk factors
in diabetic and control subjects. We believe that our finding
support the possibility that in diabetic subjects CIMT, FMD
and ABI provide independent information about the ath-
erosclerotic process. Atherosclerosis is a complex disease
and may have complex pathways in different population.
Further studies in larger scale are required to better
explain the interrelation and contribution of various risk
factors of atherosclerosis in diabetic in comparison to
control subjects.
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